CLRB: מחיר חזוי לרווח Cellectar Corp
The change in the forward P/E of Cellectar Biosciences (CLRB) on the GURU.Markets chart illustrates the market valuation trend, where 0.00 shapes the current metric. High patents and licensing requirements in radiotherapy create a steep barrier to entry in the niche. However, geopolitical tensions could disrupt raw material logistics, and the absence of commercial products leaves the budget dependent on external financing.
פילוחי מדדים ואנליטיקה של חברת Cellectar Corp (CLRB)
The forward P/E compares current market capitalization with expected earnings per share, allowing for an assessment of the asset's value relative to its future cash flows. An analysis of the consensus forward P/E for Cellectar Biosciences (CLRB) with a value of 0.00 reflects market earnings expectations, which for Cellectar Biosciences depend directly on the efficiency of ultra-fast logistics for radiopharmaceuticals with short half-lives.
